IMCLE Stock UPDATES Immunoclin Corp (IMCLE) 1.5000 08/20/2014
Post# of 273256
Posted On: 08/20/2014 8:37:54 AM
Immunoclin Corp (IMCLE) 1.5000 $IMCLE
ImmunoClin Corporation (IMCL) Announces the Appointment of Infectious Disease Expert, Dr. Heinz Ellerbrok, to the Company's Scientific Advisory Board
PR Newswire - Tue Aug 05, 10:22AM CDT
ImmunoClin Corporation (OTCBB: IMCL) is a U.S. healthcare company specializing in personalized medicine, novel anti-infectious, anti-inflammatory therapies and innovative nutritional formulations. Today, the Company is pleased to announce the appointment of Dr. Heinz Ellerbrok to its Scientific Advisory Board.
ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC
PR Newswire - Tue Jul 29, 8:21AM CDT
ImmunoClin Corporation (IMCL) is a U.S. healthcare company specializing in personalized medicine, treatment of infectious diseases as well as nutraceuticals. The company is developing strategies of prognosis and prevention of pathologies like cardiovascular disease, Alzheimer's disease and gastrointestinal disorders. As of August 1, 2014, ImmunoClin Corporation will complete the strategic relocation of its corporate headquarters to Washington, D.C., a key center of North American healthcare and biotechnology industries and related governmental agencies. In addition, the Company's chief operating officer, general counsel, and director, Chad S. Johnson, Esq., who will oversee the principal corporate office, is a decades-long D.C. resident.
ImmunoClin Corporation (IMCL) Announces the Appointment of Infectious Disease Expert, Dr. Heinz Ellerbrok, to the Company's Scientific Advisory Board
PR Newswire - Tue Aug 05, 10:22AM CDT
ImmunoClin Corporation (OTCBB: IMCL) is a U.S. healthcare company specializing in personalized medicine, novel anti-infectious, anti-inflammatory therapies and innovative nutritional formulations. Today, the Company is pleased to announce the appointment of Dr. Heinz Ellerbrok to its Scientific Advisory Board.
ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC
PR Newswire - Tue Jul 29, 8:21AM CDT
ImmunoClin Corporation (IMCL) is a U.S. healthcare company specializing in personalized medicine, treatment of infectious diseases as well as nutraceuticals. The company is developing strategies of prognosis and prevention of pathologies like cardiovascular disease, Alzheimer's disease and gastrointestinal disorders. As of August 1, 2014, ImmunoClin Corporation will complete the strategic relocation of its corporate headquarters to Washington, D.C., a key center of North American healthcare and biotechnology industries and related governmental agencies. In addition, the Company's chief operating officer, general counsel, and director, Chad S. Johnson, Esq., who will oversee the principal corporate office, is a decades-long D.C. resident.
(0)
(0)Scroll down for more posts ▼